Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome: An Analysis of the TENOR Study

Abstract

This study established directly from a randomized controlled clinical trial that tegaserod is cost-effective in the treatment of non-D-IBS patients.

Abdominal massage for people with constipation: a cost utility analysis

“…2003, Bushnell et al. 2006, Bracco et al. 2007) and found to be valid and responsive in comparison to other general as well as disease‐specific measures when it comes to IBS with constipation (Bushnell et al.…”

“…The relatively new drug tegaserod has been evaluated for cost‐effectiveness in the treatment of irritable bowel syndrome with constipation (IBS‐C) and was found to be cost‐effective in comparison with placebo (Smith et al. 2005, Bracco et al. 2007).…”

Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation

“…Bracco et al 118 (sponsored by Novartis), in an economic evaluation of tegaserod compared with placebo for IBS, evaluated the EQ-5D responses using the UK social tariff of IBS patients: 247 receiving tegaserod and 238 receiving placebo. The adjusted average baseline utility was 0.726.…”

Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis

“…58 Facing such cost concerns, modeling studies for this and other agents concluded that the increased expenses were offset by an improved quality of life and less frequent work absenteeism. [59][60][61] However, these conclusions were based upon trials without active intervention in the control group, which is unlikely to occur in clinical practice. Our results and the previously mentioned comparative trials question the validity of these models, as cheaper and effective interventions are available, and as patients seeking medical attention for symptoms of constipation will typically initiate some form of active treatment.…”